Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b, Randomized, Double-blind, Placebo-controlled, 24-week Study to Assess the Efficacy and Safety of Fezolinetant in Menopausal Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) and Considered Unsuitable for Hormone Replacement Therapy

Next Previous
Trial Profile

A Phase 3b, Randomized, Double-blind, Placebo-controlled, 24-week Study to Assess the Efficacy and Safety of Fezolinetant in Menopausal Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) and Considered Unsuitable for Hormone Replacement Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fezolinetant (Primary)
  • Indications Hot flashes; Vasomotor symptoms
  • Focus Registrational; Therapeutic Use
  • Acronyms DAYLIGHT
  • Sponsors Astellas Pharma Global Development

Most Recent Events

  • 01 Feb 2025 Results assessing Effect of fezolinetant on patient-reported quality-of-life outcomes, published in the Maturitas
  • 10 Oct 2024 According to Astellas Pharma media release,trial design will be presented during the International Menopause Society (IMS) 19th World Congress on Menopause in Melbourne, Australia, October 19-22.
  • 05 Sep 2024 According to an Astellas Pharma media release, data from this DAYLIGHT study will be presented at 2024 Annual Meeting of The Menopause Society on Thursday, Sept. 12.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top